Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions
Respirology2017Vol. 22(6), pp. 1171–1178
Citations Over TimeTop 1% of 2017 papers
Abstract
Patients with pulmonary fibrosis treated with nintedanib or pirfenidone in routine clinical practice had drug tolerability and adverse event profiles comparable with subjects enrolled in clinical trials despite having a greater degree of respiratory impairment and a high prevalence of co-morbid medical conditions.
Related Papers
- → Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis(2019)135 cited
- → Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review(2023)59 cited
- → Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions(2021)3 cited
- → Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe(2022)3 cited
- → M11 Nintedanib and pirfenidone for idiopathic pulmonary fibrosis (IPF) in north east england – real life data(2019)